Symposium II
Immune Prevention and Therapy

Programme

• 14:00 – 14:35 30 Min. 5 Min.

  • Key-Note-Lecture
  • S-2-1

  Towards a COVID-19 vaccine to protect against SARS-CoV-2 variants and animal sarbecoviruses without updating

  • Dr. Pamela Bjorkman (Pasadena/CA/ US)
• 14:35 – 14:50 10 Min. 5 Min.

  • Highlight-Vortrag
  • S-2-2

  HBs-directed T cell engager antibodies foster efficient recruitment of T cells and lead to strong reduction of hepatitis B virus infection in livers of human liver chimeric mice

  • Dr. Annika Volmari (Hamburg/ DE)

   Immune Prevention and Therapy
• 14:50 – 15:00 8 Min. 2 Min.

  • Short Talk
  • S-2-3

  MVA-MERS-S vaccine candidate elicits long-lasting memory B cell response and highly potent cross-neutralizing antibodies against zoonotic merbecoviruses

  • Dr. Matthias Zehner (Cologne/ DE)

   Immune Prevention and Therapy
• 15:00 – 15:10 8 Min. 2 Min.

  • Short Talk
  • S-2-4

  Highly-neutralizing anti-PcrV antibodies as clinical candidates against Pseudomonas aeruginosa

  • Dr. Alexander Simonis (Cologne/ DE)

   Immune Prevention and Therapy
• 15:10 – 15:20 8 Min. 2 Min.

  • Short Talk
  • S-2-5

  Preclinical development of engineered antibodies to enhancing the neutralization breath against SARS-CoV-2 emerging variants

  • Dr. Katrin Ehrhardt (Hannover/ DE)

   Immune Prevention and Therapy
• 15:20 – 15:30 8 Min. 2 Min.

  • Academy Talk
  • S-2-6

  Bispecific antibodies to combat HCMV

  • Artem Ashurov (Cologne/ DE)

   Immune Prevention and Therapy